(3R)-1,3-Dihydro-3-(1H-indol-3-ylmethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one → HCID 20063207、化合物
反応式
[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[C:3]([CH2:10][C@H:11]2[N:17]=[C:16]([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=3)[C:15]3[CH:24]=[CH:25][CH:26]=[CH:27][C:14]=3[NH:13][C:12]2=[O:28])=[CH:2]1>CCCCCC.C(OCC)(=O)C>[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[CH:3]([CH2:10][CH:11]2[N:17]=[C:16]([C:18]3[CH:19]=[CH:20][CH:21]=[CH:22][CH:23]=3)[C:15]3[CH:24]=[CH:25][CH:26]=[CH:27][C:14]=3[NH:13][C:12]2=[O:28])[CH2:2]1参加物
3
実験手順
The procedure of Example 9 was followed in which 3(R)-[(1H-indol-3-yl)methyl]-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one was reduced to give the tile compound. The analytical sample was obtained after silica gel chromatography using hexane-ethyl acetate.
後処理
- customto give the tile compound
- customThe analytical sample was obtained after silica gel chromatography